Gathering strength, peers, same frequency, win-win situation - MKK900 clinical blinding successfully completed
2025-10-15Clinical trials are a crucial step in testing the safety and efficacy of new drugs, and clinical blinding is a core step in ensuring the objectivity and reliability of test results. At the beginnin...
The application for registration of recombinant herpes zoster vaccine (CHO cell) drug has been accepted
2025-10-15On October 14, 2025, the registration application for the recombinant herpes zoster vaccine (CHO cells) independently developed by Shanghai Maikang Biotechnology Co., Ltd. (referred to as "Shanghai...
Published in the top chemistry journal! Maikokang Biological Adjuvant Team Collaborates to Publish New Adjuvant System Applied to Tumor Vaccines
2025-10-20Recently, the cooperative research paper "Enhanced Antitumor Immunity of a Globo H-Based Vaccine Enabled by the Combination Adjustments of 3D-MPL and QS-21", developed by Chengdu Maikekang Biotechn...
Zhoupu Flower Sea Team Building
2023-05-08Birds chirping and fireworks enveloping, people walking in the grass; The pond suddenly disperses, and the flowers meet again. It is April in Jiangnan, with a warm spring breeze and all things thrivin
Celebration of Corporate Culture
2023-06-09At 16:16 in the afternoon, accompanied by a cheerful rhythm of children's singing "Happy Birthday to You", the staff entered the venue on time and gathered together. 14 birthday stars were arranged in
Corporate Culture Movement
2023-06-26In the name of basketball, go on a youthful journey! On June 1st at 18:00, the 2023 Simbay Park Life Science Basketball League, sponsored by Xingbei Group and co organized by the Shanghai Pilot Free T
Yuan Quan District Chief of Fengxian District, Shanghai, led a team to investigate the use of the Maike Kang Biotechnology Shanghai production conversion platform
2024-04-20On the morning of April 20th, Yuan Quan, Deputy Secretary of the Fengxian District Committee and District Mayor of Shanghai, led a team to investigate the "Innovative Vaccine Transfer Platform" projec
The IND application for the Class I innovative drug RSV vaccine of Maikokang Biotechnology has been accepted by CDE
2024-04-12On April 12, 2024, Chengdu Maxvax Biotechnology Co., Ltd. (referred to as "Maxvax Biotechnology") announced that its independently developed and jointly applied by its wholly-owned subsidiary fo
Products Services
———— ————
留言咨询
Name*
*Phone*
*Email
Details
Copyright© 2024 Ayk Biotechnology All Rights Reserved 沪ICP备2023005885号-1
Website：jzdsh